A randomised, placebo-controlled, titration-to-effect, crossover study of study drug 038 in patients with chronic low back pai

Purdue Pharma Canada0 个研究点目标入组 100 人2008年7月4日

概览

暂无简介。

注册库

who.int

开始日期

2008年7月4日

结束日期

待定

最后更新

11年前

研究类型

Interventional

性别

All

发起方

•1\. Male or non\-pregnant females at least 18 years of age
•2\. Chronic low back pain of at least moderate intensity for at least three months
•3\. Patients who require opioids to control their pain

•1\. Patients who may require more than 12 tables of Tylenol No. 3 per day
•2\. Patients whose pain is expected to be refractory to opioid therapy
•3\. Patients with intolerance to study drug 038, acetaminophen or any other opioid
•4\. Patients with significant sources of unrelated pain that may obscure the assessment of efficacy
•5\. Patients with any of the following medical conditions:
•5\.1\. Risk for central nervous system (CNS) and/or respiratory depression
•5\.3\. Active inflammatory gastrointestinal disease
•5\.4\. Peptic ulcer disease
•5\.5\. Major psychiatric disorder
•5\.6\. Any condition that may obscure patient safety or efficacy assessment

未指定